Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scp2xx
- Development stage
- Preclinical
- Lead developer
- Silver Creek Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Scp2xx is a preclinical biologic candidate developed by Silver Creek Pharmaceuticals, designed as a half-life extended version of Hepatocyte Growth Factor (HGF). Utilizing the company's proprietary Smart-Link technology, Scp2xx is engineered to overcome the rapid systemic clearance typical of native growth factors, thereby extending its therapeutic window and enhancing its regenerative potential. HGF is a pleiotropic growth factor that signals through the MET receptor to stimulate cell proliferation, survival, and angiogenesis while simultaneously exerting anti-inflammatory and anti-fibrotic effects. Scp2xx is being developed for regenerative medicine applications, with a primary focus on treating acute organ injuries such as acute kidney injury (AKI), where sustained HGF signaling can promote tissue repair and functional recovery.
- Other names
- Smart-Link HGFhalf-life extended Hepatocyte Growth Factor
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on Scp2xx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scp2xx.